Mucopolysaccharidoses
Conditions
Brief summary
To assess the reliablity and validity of 2 new iris cameras in the assement of corneal opacification in mucopolysaccharidoses
Detailed description
The mucopolysaccharidoses (MPS) are a group of disorders resulting from accumulation of glycosaminoglycans within various tissues including the eye. This can result in visual loss from corneal opacification. The assessment of corneal opacification is extremely subjective and based on a clinician grading this during slit lamp examination. There can be a significant variability and can prove problematic particularly in clinical trials assessing if corneal opacification is affected by potential new treatments. The use of imaging could facilitate objective measurement of corneal clouding. A previous study using an iris camera and image analysis to provide a corneal opacification measure score (COM score) demonstrated that it can be used in children with MPS, however it still had limitations- as the system is fully automated, if certain conditions are not met an image is not captured. This can be an issue in younger children who may not be cooperative, and limited its use in younger patient populations. It is anticipated that these limitations can be addressed by employing a newer iris camera (IriShield MK2120UL). The new camera's advantage is that it takes images monocularly, therefore only the eye under question needs to be aligned. We will also assess a new manual system (IRcamNew) which takes images whenever the shutter is manually pressed. This would be useful in children who cannot fixate with one eye, and can also be used when the child is examined under general anaesthetic which is commonly done in paediatric ophthalmology. If proven to be comparable to the existing iris camera (IriscamOrig) in terms of validity and reliability, the added benefits of these new iris cameras can open its use in a wider range of patient populations - for instance, in paediatric clinical trials-, as well as allowing longitudinal tracking of corneal clouding from early childhood well into adulthood.
Interventions
OTHERImaging
Imaging with 3 iris cameras
Sponsors
Orchard Therapeutics
Manchester University NHS Foundation Trust
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Any patient aged 0-100 with MPS type I, type III, type IV and type VI. Type VII MPS patients may also be eligible. For the control group - Participants of any age currently being followed at MREH that have an eye condition unrelated to the cornea as established by clinical examination.
Exclusion criteria
* MPS II
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of reliability of images taken by two different operators using the two ne w iris cameras | 2 months | Bland altman plots to compare reliability between images and COM scores obtained by 2 different operators |
| Correlation of COM scores between two new iris cameras and IrisCamOrig | 2 months | Validity will be assessed by comparing the COM scores generated by the new iris cams to the previously validated iris camera |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of clinical grading to COM score obtained by image analysis | 1 month | Compare clinical grading of corneal opacification on slit lamp by clinicians to corneal opacification measure generated by image analysis |
Countries
United Kingdom
Contacts
Primary ContactJane Ashworth, MD
Outcome results
None listed